Cholinesterase inhibitors: new roles and therapeutic alt

Pharmacological Research 50, 433-440

DOI: 10.1016/j.phrs.2003.11.017

Citation Report

#	Article	IF	CITATIONS
1	Indole alkaloids from Tabernaemontana australis (M \tilde{A}^{1} /4ell. Arg) Miers that inhibit acetylcholinesterase enzyme. Bioorganic and Medicinal Chemistry, 2005, 13, 4092-4095.	1.4	104
2	New selective acetylcholinesterase inhibitors designed from natural piperidine alkaloids. Bioorganic and Medicinal Chemistry, 2005, 13, 4184-4190.	1.4	48
3	Design and synthesis of N-benzylpiperidine–purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase. Bioorganic and Medicinal Chemistry, 2005, 13, 6795-6802.	1.4	46
6	2,4-Dinitrobenzenesulfonyl Fluoresceins as Fluorescent Alternatives to Ellman's Reagent in Thiol-Quantification Enzyme Assays. Angewandte Chemie - International Edition, 2005, 44, 2922-2925.	7.2	356
8	Basal Forebrain Cholinergic Dysfunction in Alzheimer's Disease – Interrelationship with β-amyloid, Inflammation and Neurotrophin Signaling. Neurochemical Research, 2005, 30, 895-908.	1.6	151
9	Cholinesterases: Roles in the Brain During Health and Disease. Current Alzheimer Research, 2005, 2, 307-318.	0.7	303
10	Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors?. Expert Opinion on Emerging Drugs, 2005, 10, 817-825.	1.0	35
11	Inhibition of human plasma cholinesterase by malachite green and related triarylmethane dyes: Mechanistic implications. Archives of Biochemistry and Biophysics, 2005, 440, 118-122.	1.4	13
13	Novel Tacrineâ^'Melatonin Hybrids as Dual-Acting Drugs for Alzheimer Disease, with Improved Acetylcholinesterase Inhibitory and Antioxidant Properties. Journal of Medicinal Chemistry, 2006, 49, 459-462.	2.9	240
14	Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert Opinion on Investigational Drugs, 2006, 15, 1-12.	1.9	97
15	Organophosphates, Carbamates, and the Immune System. , 2006, , 495-507.		8
16	Complexes of Alkylene-Linked Tacrine Dimers withTorpedo californicaAcetylcholinesterase:Â Binding of Bis(5)-tacrine Produces a Dramatic Rearrangement in the Active-Site Gorge. Journal of Medicinal Chemistry, 2006, 49, 5491-5500.	2.9	186
18	Improving the Recognition and Management of Dementia in Long-term Care: Obstacles and Opportunities. Journal of the American Medical Directors Association, 2006, 7, 128-130.	1.2	11
19	Target-Related Applications of First Principles Quantum Chemical Methods in Drug Design. Chemical Reviews, 2006, 106, 3497-3519.	23.0	109
20	Design and activity of cationic fullerene derivatives as inhibitors of acetylcholinesterase. Organic and Biomolecular Chemistry, 2006, 4, 2556.	1.5	55
21	Effects of Cholinesterase Inhibiting Sage (Salvia officinalis) on Mood, Anxiety and Performance on a Psychological Stressor Battery. Neuropsychopharmacology, 2006, 31, 845-852.	2.8	113
22	Binding of 13-Amidohuprines to Acetylcholinesterase:Â Exploring the Ligand-Induced Conformational Change of the Gly117-Gly118 Peptide Bond in the Oxyanion Hole. Journal of Medicinal Chemistry, 2006, 49, 6833-6840.	2.9	19
23	Targeting acetylcholinesterase and butyrylcholinesterase in dementia. International Journal of Neuropsychopharmacology, 2006, 9, 101.	1.0	492

#	Article	IF	CITATIONS
24	Isoquinoline derivatives as potential acetylcholinesterase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2170-2172.	1.0	33
25	Silica-immobilized enzyme reactors; application to cholinesterase-inhibition studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 843, 310-316.	1.2	49
26	Acetylcholinesterase inhibitors from plants and fungi. Natural Product Reports, 2006, 23, 181.	5.2	489
27	Nerve Growth Factor Differentially Affects Spatial and Recognition Memory in Aged Rats. Neurochemical Research, 2006, 31, 1481-1490.	1.6	11
28	The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. Journal of Neural Transmission, 2006, 113, 1625-1644.	1.4	452
29	Pitfalls And Hopes in Down Syndrome Therapeutic Approaches: In the Search for Evidence-Based Treatments. Behavior Genetics, 2006, 36, 454-468.	1.4	17
30	Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. Neurotoxicity Research, 2006, 10, 181-192.	1.3	46
31	Kinetics of human and horse sera cholinesterases inhibition with solanaceous glycoalkaloids: Study by potentiometric biosensor. Pesticide Biochemistry and Physiology, 2006, 86, 203-210.	1.6	25
32	The Path from Anti Parkinson Drug Selegiline and Rasagiline to Multifunctional Neuroprotective Anti Alzheimer Drugs Ladostigil and M30. Current Alzheimer Research, 2006, 3, 541-550.	0.7	81
33	A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holoâ€APP translation and processing. FASEB Journal, 2006, 20, 2177-2179.	0.2	82
34	Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. Expert Review of Neurotherapeutics, 2007, 7, 473-485.	1.4	41
35	A New Bienzymatic Biosensor Based on Butyrylcholine Esteraseâ€Sulfhydryl Oxidase Enzymes. Analytical Letters, 2007, 40, 2840-2850.	1.0	3
36	Senile Dementia. , 2007, , 1-18.		0
37	Phenserine. Expert Opinion on Investigational Drugs, 2007, 16, 1087-1097.	1.9	56
38	Serum Butyrylcholinesterase is Strongly Associated with Adiposity, the Serum Lipid Profile and Insulin Resistance. Internal Medicine, 2007, 46, 1633-1639.	0.3	122
39	Multi-site inhibition of human plasma cholinesterase by cationic phenoxazine and phenothiazine dyes. Archives of Biochemistry and Biophysics, 2007, 461, 294-298.	1.4	45
40	Dialkyl phenyl phosphates as novel selective inhibitors of butyrylcholinesterase. Biochemical and Biophysical Research Communications, 2007, 355, 371-378.	1.0	17
41	l-3-n-Butylphthalide Improves Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 902-910.	1.3	96

#	Article	IF	CITATIONS
42	Targeting acetylcholinesterase to treat neurodegeneration. Expert Opinion on Therapeutic Targets, 2007, 11, 161-179.	1.5	172
43	Acetylcholinesterase Inhibitors May Improve Myelin Integrity. Biological Psychiatry, 2007, 62, 294-301.	0.7	38
44	Neuropathological and Immunochemical Studies of Brain Parenchyma in Acetylcholinesterase Knockout Mice: Implications in Alzheimer's Disease. Journal of Alzheimer's Disease, 2007, 11, 481-489.	1.2	8
45	Sensitivity of butyrylcholinesterase knockout mice to (â^²)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. Toxicology, 2007, 233, 60-69.	2.0	85
46	Synthesis and screening for acetylcholinesterase inhibitor activity of some novel 2-butyl-1,3-diaza-spiro[4,4]non-1-en-4-ones: Derivatives of irbesartan key intermediate. Bioorganic and Medicinal Chemistry, 2007, 15, 7391-7398.	1.4	17
47	Monooxime reactivators of acetylcholinesterase with (E)-but-2-ene linkerâ€"Preparation and reactivation of tabun- and paraoxon-inhibited acetylcholinesterase. Bioorganic and Medicinal Chemistry, 2007, 15, 6733-6741.	1.4	52
48	Hydrolysis of oxo- and thio-esters by human butyrylcholinesterase. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2007, 1774, 16-34.	1.1	21
49	Novel series of bispyridinium compounds bearing a (Z)-but-2-ene linkerâ€"Synthesis and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3172-3176.	1.0	40
50	Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. Journal of Neurochemistry, 2007, 100, 1421-1429.	2.1	133
51	Movement disorders: Neurodevelopment and neurobehavioural expression. Journal of Neural Transmission, 2007, 114, XXXIII-XLI.	1.4	3
52	Guanidinoacetate administration increases acetylcholinesterase activity in striatum of rats and impairs retention of an inhibitory avoidance task. Metabolic Brain Disease, 2008, 23, 189-198.	1.4	18
53	Effects of oral tetrachlorvinphos fly control (Equitrol \hat{A}°) administration in horses: Physiological and behavioural findings. Veterinary Research Communications, 2008, 32, 75-92.	0.6	8
54	RP-HPLC determination of the lipophilicity of bispyridinium reactivators of acetylcholinesterase bearing a but-2-ene connecting linker. Analytical and Bioanalytical Chemistry, 2008, 391, 367-372.	1.9	19
55	Inhibition of cholinesterase and amyloidâ€≮i>β aggregation by resveratrol oligomers from <i>Vitis amurensis</i> . Phytotherapy Research, 2008, 22, 544-549.	2.8	116
56	Homo- and hetero-bivalent edrophonium-like ammonium salts as highly potent, dual binding site AChE inhibitors. Bioorganic and Medicinal Chemistry, 2008, 16, 7450-7456.	1.4	60
57	2-Phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors: A study on the importance of modifications at the side chain on the activity. Bioorganic and Medicinal Chemistry, 2008, 16, 7646-7653.	1.4	26
58	Monoquaternary pyridinium salts with modified side chainâ€"synthesis and evaluation on model of tabun- and paraoxon-inhibited acetylcholinesterase. Bioorganic and Medicinal Chemistry, 2008, 16, 8218-8223.	1.4	25
59	Design, synthesis and evaluation of isaindigotone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3790-3793.	1.0	36

#	Article	IF	Citations
60	Tacrine based human cholinesterase inhibitors: Synthesis of peptidic-tethered derivatives and their effect on potency and selectivity. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5213-5216.	1.0	26
61	Inhibition of electric eel acetylcholinesterase by triarylmethane dyes. Chemico-Biological Interactions, 2008, 175, 309-311.	1.7	9
62	The level of butyrylcholinesterase activity increases and the content of the mRNA remains unaffected in brain of senescence-accelerated mouse SAMP8. Chemico-Biological Interactions, 2008, 175, 332-335.	1.7	6
63	Cognition enhancers between treating and doping the mind. Pharmacological Research, 2008, 57, 196-213.	3.1	114
64	Exploiting Protein Fluctuations at the Active-Site Gorge of Human Cholinesterases: Further Optimization of the Design Strategy to Develop Extremely Potent Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 3154-3170.	2.9	56
65	Progress in acetylcholinesterase inhibitors for Alzheimer's disease: an update. Expert Opinion on Therapeutic Patents, 2008, 18, 387-401.	2.4	30
66	Benzofuran-Based Hybrid Compounds for the Inhibition of Cholinesterase Activity, \hat{l}^2 Amyloid Aggregation, and $A\hat{l}^2$ Neurotoxicity. Journal of Medicinal Chemistry, 2008, 51, 2883-2886.	2.9	181
67	ATP and acetylcholine, equal brethren. Neurochemistry International, 2008, 52, 634-648.	1.9	70
68	Choline availability and acetylcholine synthesis in the hippocampus of acetylcholinesterase-deficient mice. Neurochemistry International, 2008, 52, 972-978.	1.9	28
69	Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase. Archives of Biochemistry and Biophysics, 2008, 478, 201-205.	1.4	23
70	Inhibition of acetylcholinesterase by coumarins: The case of coumarin 106. Pharmacological Research, 2008, 58, 215-221.	3.1	66
71	Chapter 1 Cholinergic components of frontal lobe function and dysfunction. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 88, 1-30.	1.0	2
72	Novel Donepezil-Based Inhibitors of Acetyl- and Butyrylcholinesterase and Acetylcholinesterase-Induced \hat{l}^2 -Amyloid Aggregation. Journal of Medicinal Chemistry, 2008, 51, 3588-3598.	2.9	186
73	Huprines for Alzheimer's disease drug development. Expert Opinion on Drug Discovery, 2008, 3, 65-81.	2.5	19
74	Treatment Options in Alzheimer's Disease: Maximizing Benefit, Managing Expectations. Dementia and Geriatric Cognitive Disorders, 2008, 25, 408-422.	0.7	109
75	Bioinformatic Analysis of Alzheimer's Disease Using Functional Protein Sequences. Journal of Proteomics and Bioinformatics, 2008, 01, 036-042.	0.4	8
76	Silica-Immobilized Enzyme Reactors. Journal of Liquid Chromatography and Related Technologies, 2008, 31, 1568-1592.	0.5	23
77	Anti-Inflammatory Properties of Acetylcholinesterase Inhibitors Administred in Alzheimers Disease. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2009, 8, 85-100.	1.1	10

#	ARTICLE	IF	Citations
78	Effects of Rivastigmine and Donepezil on Brain Acetylcholine Levels in Acetylcholinesterase-Deficient Mice. Journal of Pharmacy and Pharmaceutical Sciences, 2009, 12, 79.	0.9	45
79	Synthesis and biological evaluation of novel flavonoid derivatives as dual binding acetylcholinesterase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 372-380.	2.5	42
80	Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions. Biochemical Journal, 2009, 417, 213-222.	1.7	28
81	Traditional Medicine for Memory Enhancement. , 2009, , 239-291.		11
82	Long-lasting decreases in cocaine-reinforced behavior following treatment with the cholinesterase inhibitor tacrine in rats selectively bred for drug self-administration. Pharmacology Biochemistry and Behavior, 2009, 94, 169-178.	1.3	13
83	Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. Journal of Neural Transmission, 2009, 116, 457-465.	1.4	135
84	Novel 16-substituted bifunctional derivatives of huperzine B: multifunctional cholinesterase inhibitors. Acta Pharmacologica Sinica, 2009, 30, 1195-1203.	2.8	16
85	Chitooligosaccharides suppress the level of protein expression and acetylcholinesterase activity induced by Al̂²25–35 in PC12 cells. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 860-862.	1.0	40
86	Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5528-5530.	1.0	38
87	Content of Individual Phenolic Acids in Worts and Beers and their Possible Contribution to the Antiradical Activity of Beer. Journal of the Institute of Brewing, 2009, 115, 243-252.	0.8	34
88	Effect of distigmine bromide on the central cholinergic system. Journal of Psychopharmacology, 2009, 23, 190-193.	2.0	5
89	Modeling cholinergic aspects of schizophrenia: Focus on the antimuscarinic syndrome. Behavioural Brain Research, 2009, 204, 335-351.	1.2	43
90	Pyrano[3,2- <i>c</i>)quinolineâ^6-Chlorotacrine Hybrids as a Novel Family of Acetylcholinesterase- and β-Amyloid-Directed Anti-Alzheimer Compounds. Journal of Medicinal Chemistry, 2009, 52, 5365-5379.	2.9	164
91	Cholinergic Functioning in Stimulant Addiction. CNS Drugs, 2009, 23, 939-952.	2.7	61
92	Pharmacological Overview and Future Perspectives of Cholinergic Therapy in Alzheimers Disease. Current Drug Therapy, 2009, 4, 65-72.	0.2	1
93	Cognitive function as an emerging treatment target for marijuana addiction Experimental and Clinical Psychopharmacology, 2010, 18, 109-119.	1.3	57
94	Bivalent \hat{I}^2 -Carbolines as Potential Multitarget Anti-Alzheimer Agents. Journal of Medicinal Chemistry, 2010, 53, 3611-3617.	2.9	128
95	1,2,3,4,6-penta-O-galloyl-Î ² -d-glucose: A cholinesterase inhibitor from Terminalia chebula. South African Journal of Botany, 2010, 76, 285-288.	1.2	55

#	Article	IF	CITATIONS
96	Neuroprotective effects of icariin on memory impairment and neurochemical deficits in senescence-accelerated mouse prone 8 (SAMP8) mice. Brain Research, 2010, 1334, 73-83.	1.1	44
97	Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates. Chemico-Biological Interactions, 2010, 187, 411-415.	1.7	71
98	Monooximeâ€monocarbamoyl Bispyridinium Xyleneâ€Linked Reactivators of Acetylcholinesteraseâ€"Synthesis, In vitro and Toxicity Evaluation, and Docking Studies. ChemMedChem, 2010, 5, 247-254.	1.6	38
99	Novel Huprine Derivatives with Inhibitory Activity toward βâ€Amyloid Aggregation and Formation as Diseaseâ€Modifying Antiâ€Alzheimer Drug Candidates. ChemMedChem, 2010, 5, 1855-1870.	1.6	56
100	Quantification of acetylcholine, an essential neurotransmitter, in brain microdialysis samples by liquid chromatography mass spectrometry. Biomedical Chromatography, 2010, 24, 39-48.	0.8	43
101	Cholinesterase activity in brain of senescenceâ€acceleratedâ€resistant mouse SAMR1 and its variation in brain of senescenceâ€acceleratedâ€prone mouse SAMP8. Journal of Neuroscience Research, 2010, 88, 155-166.	1.3	13
102	Berberine derivatives, with substituted amino groups linked at the 9-position, as inhibitors of acetylcholinesterase/butyrylcholinesterase. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6649-6652.	1.0	32
103	Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction, 2010, 105, 38-48.	1.7	145
104	Enzymatic production of bioactive protein hydrolysates from tuna liver: effects of enzymes and molecular weight on bioactivity. International Journal of Food Science and Technology, 2010, 45, 562-568.	1.3	49
105	<i>In vivo</i> labelling of hippocampal βâ€amyloid in tripleâ€transgenic mice with a fluorescent acetylcholinesterase inhibitor released from nanoparticles. European Journal of Neuroscience, 2010, 31, 99-109.	1.2	23
106	Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents. Current Pharmaceutical Design, 2010, 16, 2818-2836.	0.9	51
107	Cryptotanshinone, an Acetylcholinesterase Inhibitor from (i>Salvia miltiorrhiza (/i>, Ameliorates Scopolamine-Induced Amnesia in Morris Water Maze Task. Planta Medica, 2010, 76, 228-234.	0.7	69
108	Morbus Alzheimer — Epidemiologie, Diagnose und Therapie. Zentralblatt Fur Arbeitsmedizin, Arbeitsschutz Und Ergonomie, 2010, 60, 92-99.	0.1	0
109	A naked-eye visible and fluorescence "turn-on―probe for acetyl-cholinesterase assay and thiols as well as imaging of living cells. Analyst, The, 2011, 136, 191-195.	1.7	61
111	The Use of Cholinesterases in Ecotoxicology. Reviews of Environmental Contamination and Toxicology, 2011, 212, 29-59.	0.7	66
112	Neuroscience of Behavioral and Pharmacological Treatments for Addictions. Neuron, 2011, 69, 695-712.	3.8	188
113	Reversible and persistent decreases in cocaine self-administration after cholinesterase inhibition. Behavioural Pharmacology, 2011, 22, 58-70.	0.8	15
114	Galantamine improves sustained attention in chronic cocaine users Experimental and Clinical Psychopharmacology, 2011, 19, 11-19.	1.3	37

#	ARTICLE	IF	CITATIONS
115	Different sensitivities of rat skeletal muscles and brain to novel antiâ€cholinesterase agents, alkylammonium derivatives of 6â€methyluracil (ADEMS). British Journal of Pharmacology, 2011, 163, 732-744.	2.7	14
116	Effects of Galantamine on Cocaine Use in Chronic Cocaine Users. American Journal on Addictions, 2011, 20, 302-303.	1.3	24
117	Multi-target strategy to address Alzheimer's disease: Design, synthesis and biological evaluation of new tacrine-based dimers. European Journal of Medicinal Chemistry, 2011, 46, 4336-4343.	2.6	37
118	Anticholinesterase activity of standardized extract of Illicium verum Hook. f. fruits. Fìtoterapìâ, 2011, 82, 342-346.	1.1	53
119	Bisindole alkaloids and secoiridoids from Alstonia macrophylla Wall. ex G. Don. Fìtoterapìâ, 2011, 82, 798-804.	1.1	25
120	Selective cholinesterase inhibition by lanostane triterpenes from fruiting bodies of Ganoderma lucidum. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6603-6607.	1.0	69
121	Brominated Extracts As Source of Bioactive Compounds. ACS Combinatorial Science, 2011, 13, 200-204.	3.8	25
122	Chemically Engineered Extracts: Source of Bioactive Compounds. Accounts of Chemical Research, 2011, 44, 241-250.	7.6	66
123	3D-pharmacophore model based virtual screening to identify dual-binding site and selective acetylcholinesterase inhibitors. Medicinal Chemistry Research, 2011, 20, 1422-1430.	1.1	13
124	Synthesis, biological assessment and molecular modeling of new dihydroquinoline-3-carboxamides and dihydroquinoline-3-carbohydrazide derivatives as cholinesterase inhibitors, and Ca channel antagonists. European Journal of Medicinal Chemistry, 2011, 46, 1-10.	2.6	46
125	<i>In vivo</i> brain microdialysis: advances in neuropsychopharmacology and drug discovery. Expert Opinion on Drug Discovery, 2011, 6, 109-127.	2.5	61
126	Anticholinesterase Activity of <i> Astragalus gombiformis < /i > Extracts. Journal of Biologically Active Products From Nature, 2011, 1, 344-348.</i>	0.1	3
127	Cholinesterase inhibition activity of <i>Marsilea quadrifolia </i> Linn. an edible leafy vegetable from West Bengal, India. Natural Product Research, 2012, 26, 1519-1522.	1.0	17
128	Efficient Near-Infrared In Vivo Imaging of Amyoid-Î ² Deposits in Alzheimer's Disease Mouse Models. Journal of Alzheimer's Disease, 2012, 30, 651-664.	1.2	31
129	A Single-Center, Randomized, Open-Label, Dose-Escalation Study to Evaluate the Pharmacokinetics of Tacrine Analogue Octahydrogenacridine Succinate Tablets in Healthy Chinese Subjects. Biological and Pharmaceutical Bulletin, 2012, 35, 1502-1508.	0.6	2
130	l-3-n-butylphthalide improves cognitive deficits in rats with chronic cerebral ischemia. Neuropharmacology, 2012, 62, 2424-2429.	2.0	54
131	Synthesis, characterization and distinct butyrylcholinesterase activities of transition metal complexes of 2-[(E)-(quinolin-3-ylimino)methyl]phenol. Inorganica Chimica Acta, 2012, 390, 210-216.	1.2	20
132	Design, synthesis, and bioevaluation of benzamides: Novel acetylcholinesterase inhibitors with multi-functions on butylcholinesterase, $\hat{Al^2}$ aggregation, and $\hat{l^2}$ -secretase. Bioorganic and Medicinal Chemistry, 2012, 20, 6739-6750.	1.4	39

#	Article	IF	CITATIONS
133	Hologram QSAR Models of 4-[(Diethylamino)methyl]-phenol Inhibitors of Acetyl/Butyrylcholinesterase Enzymes as Potential Anti-Alzheimer Agents. Molecules, 2012, 17, 9529-9539.	1.7	21
134	Metal Ions in Neurological Systems. , 2012, , .		12
135	In Vitro /em> Anticholinergic and Antihistaminic Activities of Acorus Calamus /em> Linn. Leaves Extracts. Tropical Journal of Obstetrics and Gynaecology, 2012, 10, .	0.3	5
136	Phenolic acids from malt are efficient acetylcholinesterase and butyrylcholinesterase inhibitors. Journal of the Institute of Brewing, 2012, 118, 40-48.	0.8	68
137	New cholinesterase inhibiting bisbenzylisoquinoline alkaloids from Abuta grandifolia. Fìtoterapìâ, 2012, 83, 476-480.	1.1	24
138	Anticholinesterase potential of flavonols from paper mulberry (Broussonetia papyrifera) and their kinetic studies. Food Chemistry, 2012, 132, 1244-1250.	4.2	61
139	Comparative assessment of antioxidant and cholinesterase inhibitory properties of the marigold extracts from Calendula arvensis L. and Calendula officinalis L Industrial Crops and Products, 2012, 36, 203-208.	2.5	57
140	Identification and characterization of diarylimidazoles as hybrid inhibitors of butyrylcholinesterase and amyloid beta fibril formation. European Journal of Pharmaceutical Sciences, 2012, 45, 169-183.	1.9	27
141	The exploration of thienothiazines as selective butyrylcholinesterase inhibitors. European Journal of Pharmaceutical Sciences, 2012, 47, 190-205.	1.9	36
142	Esterase profile of O-phosphorylated ethyltrifluorolactates in prediction of their therapeutic and toxic effects. Doklady Biochemistry and Biophysics, 2012, 443, 81-85.	0.3	8
143	Molecular design of O-phosphorylated oximesâ€"Selective inhibitors of butyrylcholinesterase. Doklady Biochemistry and Biophysics, 2012, 443, 91-95.	0.3	10
144	Recent advances in the multitargetâ€directed ligands approach for the treatment of Alzheimer's disease. Medicinal Research Reviews, 2013, 33, 139-189.	5.0	394
145	An expedient, ionic liquid mediated multi-component synthesis of novel piperidone grafted cholinesterase enzymes inhibitors and their molecular modeling study. European Journal of Medicinal Chemistry, 2013, 67, 221-229.	2.6	43
146	Microwave assisted synthesis, cholinesterase enzymes inhibitory activities and molecular docking studies of new pyridopyrimidine derivatives. Bioorganic and Medicinal Chemistry, 2013, 21, 3022-3031.	1.4	31
147	The Correlative Study of Serum Pseudo-cholinesterase, Biological Parameters and Symptoms Among Occupational Workers. Indian Journal of Clinical Biochemistry, 2013, 28, 396-402.	0.9	1
148	Antioxidant potentials and anticholinesterase activities of methanolic and aqueous extracts of three endemic Centaurea L. species. Food and Chemical Toxicology, 2013, 55, 290-296.	1.8	175
149	Design, synthesis, biological evaluation and docking study of 5-oxo-4,5-dihydropyrano[3,2-c]chromene derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors. European Journal of Medicinal Chemistry, 2013, 68, 260-269.	2.6	91
150	Synthesis of Some New 3â€ <scp>C</scp> oumaranone and Coumarin Derivatives as Dual Inhibitors of Acetyl―and Butyrylcholinesterase. Archiv Der Pharmazie, 2013, 346, 577-587.	2.1	27

#	ARTICLE	IF	CITATIONS
151	Effect of maternal deprivation on acetylcholinesterase activity and behavioral changes on the ketamine-induced animal model of schizophrenia. Neuroscience, 2013, 248, 252-260.	1.1	19
152	Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype., 2013, 9, e17-e73.		30
153	The role of serum albumin in the metabolism of Boc5: Molecular identification, species differences and contribution to plasma metabolism. European Journal of Pharmaceutical Sciences, 2013, 48, 360-369.	1.9	19
154	N,N-disubstituted 2-aminothiazolines as new inhibitors of serine esterases. Doklady Biochemistry and Biophysics, 2013, 451, 209-211.	0.3	7
155	Modeling Alzheimer's disease in transgenic rats. Molecular Neurodegeneration, 2013, 8, 37.	4.4	144
156	Two new phthalides with BuChE inhibitory activity from <i>Ligusticum chuanxiong</i> . Journal of Asian Natural Products Research, 2013, 15, 1237-1242.	0.7	14
157	Age-related changes in rostral basal forebrain cholinergic and GABAergic projection neurons: relationship with spatial impairment. Neurobiology of Aging, 2013, 34, 845-862.	1.5	37
158	Mice heterozygous for AChE are more sensitive to AChE inhibitors but do not respond to BuChE inhibition. Neuropharmacology, 2013, 67, 37-45.	2.0	23
159	Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors. European Journal of Medicinal Chemistry, 2013, 70, 623-630.	2.6	106
160	Effect of viologen–phosphorus dendrimers on acetylcholinesterase and butyrylcholinesterase activities. International Journal of Biological Macromolecules, 2013, 54, 119-124.	3.6	22
161	Determination of binding points of methylene blue and cationic phenoxazine dyes on human butyrylcholinesterase. Archives of Biochemistry and Biophysics, 2013, 532, 32-38.	1.4	10
162	Cholinergic modulation of primary afferent glutamatergic transmission in rat medullary dorsal horn neurons. Neuropharmacology, 2013, 75, 295-303.	2.0	11
163	Synthesis and biological evaluation of 1, 3-dihydroxyxanthone mannich base derivatives as anticholinesterase agents. Chemistry Central Journal, 2013, 7, 78.	2.6	32
164	Specifically Monitoring Butyrylcholinesterase by Supramolecular Tandem Assay. Chemistry - A European Journal, 2013, 19, 8755-8759.	1.7	42
165	Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes. Journal of Alzheimer's Disease, 2013, 33, 547-658.	1.2	21
166	Cholinergic Modulation by Opioid Receptor Ligands: Potential Application to Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry, 2013, 13, 456-466.	1.1	7
167	Structure-Based Search for New Inhibitors of Cholinesterases. International Journal of Molecular Sciences, 2013, 14, 5608-5632.	1.8	200
169	Acetylcholinesterase inhibitors used or tested in Alzheimers disease therapy; their passive diffusion through blood brain barrier: In vitro study. African Journal of Pharmacy and Pharmacology, 2013, 7, 1471-1481.	0.2	4

#	ARTICLE	IF	CITATIONS
170	Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer's Disease. Current Medicinal Chemistry, 2014, 22, 373-404.	1.2	271
171	The Effects of Sesquiterpenes-Rich Extract of <i>Alpinia oxyphylla </i> Miq. on Amyloid- <i<math>\hat{l}^2</i<math> -Induced Cognitive Impairment and Neuronal Abnormalities in the Cortex and Hippocampus of Mice. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-11.	1.9	34
172	Acetylcholinesterase and Butyrylcholinesterase Inhibitory Properties of Functionalized Tetrahydroacridines and Related Analogs. , 2014, 4, .		17
173	Specific Cholinesterase Inhibitors: A Potential Tool to Assist in Management of Alzheimer Disease. , 2014, , 366-386.		5
174	Enzyme Inhibitors Involved in the Treatment of Alzheimer's Disease., 2014,, 142-198.		1
175	Dual Binding Site and Selective Acetylcholinesterase Inhibitors Derived from Integrated Pharmacophore Models and Sequential Virtual Screening. BioMed Research International, 2014, 2014, 1-21.	0.9	34
176	Volatile Profiling of Aromatic Traditional Medicinal Plant, Polygonum minus in Different Tissues and Its Biological Activities. Molecules, 2014, 19, 19220-19242.	1.7	41
177	Long-Term Effects of Maternal Deprivation on Cholinergic System in Rat Brain. BioMed Research International, 2014, 2014, 1-7.	0.9	8
178	Biological Evaluation of Endophytic Fungus, Chaetomium globosum JN711454, as Potential Candidate for Improving Drug Discovery. Cell Biochemistry and Biophysics, 2014, 68, 67-82.	0.9	28
179	Cholinesterase inhibitory activity versus aromatic core multiplicity: A facile green synthesis and molecular docking study of novel piperidone embedded thiazolopyrimidines. Bioorganic and Medicinal Chemistry, 2014, 22, 906-916.	1.4	19
180	Synthesis, cytotoxicity and molecular modelling studies of new phenylcinnamide derivatives as potent inhibitors of cholinesterases. European Journal of Medicinal Chemistry, 2014, 78, 43-53.	2.6	44
181	Future pharmacological treatments for substance use disorders. British Journal of Clinical Pharmacology, 2014, 77, 382-400.	1.1	48
182	Design, synthesis and evaluation of novel tacrineâ€"rhein hybrids as multifunctional agents for the treatment of Alzheimer's disease. Organic and Biomolecular Chemistry, 2014, 12, 801-814.	1.5	73
183	Cyclic acyl guanidines bearing carbamate moieties allow potent and dirigible cholinesterase inhibition of either acetyl- or butyrylcholinesterase. Bioorganic and Medicinal Chemistry, 2014, 22, 5020-5034.	1.4	14
184	Prenylated xanthones from mangosteen as promising cholinesterase inhibitors and their molecular docking studies. Phytomedicine, 2014, 21, 1303-1309.	2.3	60
185	Beta and gamma carboline derivatives as potential anti-Alzheimer agents: A comparison. European Journal of Medicinal Chemistry, 2014, 87, 63-70.	2.6	71
186	Syntheses of coumarin–tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and β-secretase. Bioorganic and Medicinal Chemistry, 2014, 22, 4784-4791.	1.4	77
187	Prospective neurobiological effects of the aerial and root extracts and some pure compounds of randomly selected <i>Scorzonera </i>) species. Pharmaceutical Biology, 2014, 52, 873-882.	1.3	15

#	Article	IF	CITATIONS
188	Sulforaphane alleviates scopolamine-induced memory impairment in mice. Pharmacological Research, 2014, 85, 23-32.	3.1	64
189	New insights on Alzheimer's disease. Journal of Microscopy and Ultrastructure, 2014, 2, 57.	0.1	6
190	Immobilized cholinesterases capillary reactors on-flow screening of selective inhibitors. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 968, 87-93.	1.2	17
191	Identification of a neuroprotective and selective butyrylcholinesterase inhibitor derived from the natural alkaloid evodiamine. European Journal of Medicinal Chemistry, 2014, 81, 15-21.	2.6	63
192	New cholinesterase inhibitors from Garcinia atroviridis. Fìtoterapìâ, 2014, 97, 261-267.	1.1	20
193	Synthesis of \hat{l}_{\pm} , \hat{l}^2 -unsaturated carbonyl based compounds as acetylcholinesterase and butyrylcholinesterase inhibitors: Characterization, molecular modeling, QSAR studies and effect against amyloid \hat{l}^2 -induced cytotoxicity. European Journal of Medicinal Chemistry, 2014, 83, 355-365.	2.6	44
194	Influence of cholinesterase inhibitors, donepezil and rivastigmine on the acquisition, expression, and reinstatement of morphine-induced conditioned place preference in rats. Behavioural Brain Research, 2014, 268, 169-176.	1.2	24
195	Acetylcholinesterase Inhibitory Activity of Pigment Echinochrome A from Sea Urchin Scaphechinus mirabilis. Marine Drugs, 2014, 12, 3560-3573.	2.2	31
196	Esterase profiles of hexafluoropropan-2-ol-based dialkyl phosphates as a major determinant of their effects in mouse brain in vivo. Russian Chemical Bulletin, 2015, 64, 2203-2209.	0.4	2
197	T cell immunity to glatiramer acetate ameliorates cognitive deficits induced by chronic cerebral hypoperfusion by modulating the microenvironment. Scientific Reports, 2015, 5, 14308.	1.6	17
198	Synthesis and DPPH scavenging assay of reserpine analogues, computational studies and in silico docking studies in AChE and BChE responsible for Alzheimer's disease. Brazilian Journal of Pharmaceutical Sciences, 2015, 51, 53-61.	1.2	5
199	Development and Structural Modifications of Cholinesterase Reactivators against Chemical Warfare Agents in Last Decade: A Review. Mini-Reviews in Medicinal Chemistry, 2015, 15, 58-72.	1.1	53
200	An Expedient Synthesis, Acetylcholinesterase Inhibitory Activity, and Molecular Modeling Study of Highly Functionalized Hexahydro-1,6-naphthyridines. BioMed Research International, 2015, 2015, 1-9.	0.9	14
201	Ameliorating Effects of Ethanol Extract ofFructus mumeon Scopolamine-Induced Memory Impairment in Mice. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-8.	0.5	14
202	Rational drug discovery design approaches for treating Parkinson's disease. Expert Opinion on Drug Discovery, 2015, 10, 713-741.	2.5	16
203	Discovering New Acetylcholinesterase Inhibitors by Mining the <i>Buzhongyiqi</i> Decoction Recipe Data. Journal of Chemical Information and Modeling, 2015, 55, 2455-2463.	2.5	23
204	New Indole Alkaloids from the Bark of Rauvolfia Reflexa and their Cholinesterase Inhibitory Activity. Cellular Physiology and Biochemistry, 2015, 37, 1997-2011.	1.1	31
205	Synthesis of some 3(2H)-pyridazinone and 1(2H)-phthalazinone derivatives incorporating aminothiazole moiety and investigation of their antioxidant, acetylcholinesterase, and butyrylcholinesterase inhibitory activities. Medicinal Chemistry Research, 2015, 24, 1210-1217.	1.1	17

#	Article	IF	CITATIONS
206	Exploration of a library of triazolothiadiazole and triazolothiadiazine compounds as a highly potent and selective family of cholinesterase and monoamine oxidase inhibitors: design, synthesis, X-ray diffraction analysis and molecular docking studies. RSC Advances, 2015, 5, 21249-21267.	1.7	45
207	Multifunctional tacrine–trolox hybrids for the treatment of Alzheimer's disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties. European Journal of Medicinal Chemistry, 2015, 93, 42-50.	2.6	69
208	Design, synthesis and in vitro testing of 7-methoxytacrine-amantadine analogues: a novel cholinesterase inhibitors for the treatment of Alzheimer's disease. Medicinal Chemistry Research, 2015, 24, 2645-2655.	1.1	28
209	Development of multifunctional, heterodimeric isoindoline-1,3-dione derivatives as cholinesterase and \hat{l}^2 -amyloid aggregation inhibitors with neuroprotective properties. European Journal of Medicinal Chemistry, 2015, 92, 738-749.	2.6	60
210	Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans. Psychopharmacology, 2015, 232, 343-353.	1.5	26
211	Dementiasâ~†., 2015, , .		0
212	Butyrylcholinesterase genotype and enzyme activity in relation to Gulf War illness: preliminary evidence of gene-exposure interaction from a case–control study of 1991 Gulf War veterans. Environmental Health, 2015, 14, 4.	1.7	44
213	Synthesis and investigation of biological activity of phosphorylated amines and amides. Russian Journal of General Chemistry, 2015, 85, 1644-1649.	0.3	10
214	Cholinesterase inhibitory triterpenoids from the bark of i> Garcinia hombroniana in Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 133-139.	2.5	42
215	Discovery of butyrylcholinesterase inhibitors among derivatives of azaphenothiazines. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 98-106.	2.5	19
216	Acetylcholinesterase enzyme inhibitor activity of some novel pyrazinamide condensed 1,2,3,4-tetrahydropyrimidines. Biotechnology Reports (Amsterdam, Netherlands), 2015, 5, 1-6.	2.1	18
217	Antinociceptive and anti-inflammatory effects of a Geissospermum vellosii stem bark fraction. Anais Da Academia Brasileira De Ciencias, 2016, 88, 237-248.	0.3	9
218	Synthesis, Molecular Modelling and Biological Evaluation of Novel Heterodimeric, Multiple Ligands Targeting Cholinesterases and Amyloid Beta. Molecules, 2016, 21, 410.	1.7	29
219	Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 1059-1071.	1.4	42
220	Design, synthesis and cholinesterase inhibitory evaluation study of fluorescent N-benzylpiperidine-4-one derivatives. Medicinal Chemistry Research, 2016, 25, 1705-1715.	1.1	5
221	Phthalimideâ€Derived <i>N</i> à€Benzylpyridinium Halides Targeting Cholinesterases: Synthesis and Bioactivity of New Potential Antiâ€Alzheimer's Disease Agents. Archiv Der Pharmazie, 2016, 349, 293-301.	2.1	20
222	1,2,4-Thiadiazoles as promising multifunctional agents for treatment of neurodegenerative diseases. Russian Chemical Bulletin, 2016, 65, 1586-1591.	0.4	11
223	Computation of Pharmacologic Therapy Effects on Cognitive Abilities of Alzheimer's Disease Patients. , 2016, , .		1

#	Article	IF	CITATIONS
224	Synthesis and studies of biological activity of N-(4-tert-butylbenzyl)-N-(pyridin-3-ylmethyl)-2-aminothiazolines as potential multifunctional agents for treatment of neurodegenerative diseases. Russian Chemical Bulletin, 2016, 65, 1341-1345.	0.4	2
225	Acquisition and reinstatement of ethanol-induced conditioned place preference in rats: Effects of the cholinesterase inhibitors donepezil and rivastigmine. Journal of Psychopharmacology, 2016, 30, 676-687.	2.0	7
226	Development of cyanopyridine–triazine hybrids as lead multitarget anti-Alzheimer agents. Bioorganic and Medicinal Chemistry, 2016, 24, 2777-2788.	1.4	48
227	Natural cholinesterase inhibitors from Myristica cinnamomea King. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3785-3792.	1.0	20
228	Biological evaluation of synthetic $\hat{l}\pm,\hat{l}^2$ -unsaturated carbonyl based cyclohexanone derivatives as neuroprotective novel inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid- \hat{l}^2 aggregation. Bioorganic and Medicinal Chemistry, 2016, 24, 2352-2359.	1.4	31
229	Esterase profiles of organophosphorus compounds inÂvitro predict their behavior inÂvivo. Chemico-Biological Interactions, 2016, 259, 332-342.	1.7	58
230	Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies. European Journal of Medicinal Chemistry, 2016, 119, 260-277.	2.6	55
231	Tomato plant leaves: From by-products to the management of enzymes in chronic diseases. Industrial Crops and Products, 2016, 94, 621-629.	2.5	29
232	Copper (II) and zinc (II) complexes with flavanone derivatives: Identification of potential cholinesterase inhibitors by on-flow assays. Journal of Inorganic Biochemistry, 2016, 164, 141-149.	1.5	20
233	Synthesis, characterization and in vitro evaluation of substituted N-(2-phenylcyclopropyl)carbamates as acetyl- and butyrylcholinesterase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 173-179.	2.5	8
234	DL0410, a novel dual cholinesterase inhibitor, protects mouse brains against $\hat{Al^2}$ -induced neuronal damage via the Akt/JNK signaling pathway. Acta Pharmacologica Sinica, 2016, 37, 1401-1412.	2.8	29
235	Evaluation of multifunctional synthetic tetralone derivatives for treatment of Alzheimer's disease. Chemical Biology and Drug Design, 2016, 88, 889-898.	1.5	22
236	1H-benzimidazole derivatives as butyrylcholinesterase inhibitors: synthesis and molecular modeling studies. Medicinal Chemistry Research, 2016, 25, 2005-2014.	1.1	21
237	Toluidine blue O is a potent inhibitor of human cholinesterases. Archives of Biochemistry and Biophysics, 2016, 604, 57-62.	1.4	12
238	Monte Carlo-based QSAR modeling of dimeric pyridinium compounds and drug design of new potent acetylcholine esterase inhibitors for potential therapy of myasthenia gravis. Structural Chemistry, 2016, 27, 1511-1519.	1.0	26
239	Chemical components from the seeds of Catalpa bungei and their inhibitions of soluble epoxide hydrolase, cholinesterase and nuclear factor kappa B activities. RSC Advances, 2016, 6, 40706-40716.	1.7	13
240	Acetylcholinesteraseâ€inhibitor hydrolysates obtained from â€~ <i>inÂvitro</i> àê™ enzymatic hydrolysis of mannoproteins extracted from different strains of yeasts. International Journal of Food Science and Technology, 2016, 51, 300-308.	1.3	5
241	Synthesis, molecular docking and biological evaluation of N,N-disubstituted 2-aminothiazolines as a new class of butyrylcholinesterase and carboxylesterase inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 1050-1062.	1.4	57

#	Article	IF	CITATIONS
242	Rg3-enriched ginseng extract ameliorates scopolamine-induced learning deficits in mice. BMC Complementary and Alternative Medicine, 2016, 16, 66.	3.7	25
243	Design, synthesis and biological evaluation of novel donepezil–coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2016, 24, 1528-1539.	1.4	72
244	In vitro anti-cholinesterase and anti-hyperglycemic activities of flowers extracts from seven pomegranate varieties. Industrial Crops and Products, 2016, 81, 176-179.	2.5	24
245	Effect of piracetam, vincamine, vinpocetine, and donepezil on oxidative stress and neurodegeneration induced by aluminum chloride in rats. Comparative Clinical Pathology, 2016, 25, 305-318.	0.3	37
246	Current and novel therapeutic molecules and targets in Alzheimer's disease. Journal of the Formosan Medical Association, 2016, 115, 3-10.	0.8	111
247	Development and characterization of morin hydrate loaded microemulsion for the management of Alzheimer's disease. Artificial Cells, Nanomedicine and Biotechnology, 2017, 45, 1620-1630.	1.9	25
249	Arylidene indanone scaffold: medicinal chemistry and structure–activity relationship view. RSC Advances, 2017, 7, 9357-9372.	1.7	54
250	New tacrine-derived AChE/BuChE inhibitors: Synthesis and biological evaluation of 5-amino-2-phenyl-4H-pyrano[2,3-b]quinoline-3-carboxylates. European Journal of Medicinal Chemistry, 2017, 128, 237-246.	2.6	41
251	Synthesis and biological evaluation of 8-hydroxy-2,7-naphthyridin-2-ium salts as novel inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). MedChemComm, 2017, 8, 465-470.	3.5	3
252	Pharmacology of mangostins and their derivatives: A comprehensive review. Chinese Journal of Natural Medicines, 2017, 15, 81-93.	0.7	47
253	An on-flow assay for screening of \hat{l}^2 -secretase ligands by immobilised capillary reactor-mass spectrometry. Analytical Methods, 2017, 9, 2189-2196.	1.3	10
254	Prediction of Antiâ€Alzheimer's Activity of Flavonoids Targeting Acetylcholinesterase <i>in silico</i> . Phytochemical Analysis, 2017, 28, 324-331.	1.2	41
255	Aqueous extracts from asparagus stems prevent memory impairments in scopolamine-treated mice. Food and Function, 2017, 8, 1460-1467.	2.1	26
256	Journal of Chemical Research, 2017, 41, 120-123.	0.6	5
257	Discorhabdin alkaloids from Antarctic Latrunculia spp. sponges as a new class of cholinesterase inhibitors. European Journal of Medicinal Chemistry, 2017, 136, 294-304.	2.6	28
258	Novel bipharmacophoric inhibitors of the cholinesterases with affinity to the muscarinic receptors M ₁ and M ₂ . MedChemComm, 2017, 8, 1346-1359.	3.5	10
259	Ellagitannin and flavonoid constituents from Agrimonia pilosa Ledeb. with their protein tyrosine phosphatase and acetylcholinesterase inhibitory activities. Bioorganic Chemistry, 2017, 72, 293-300.	2.0	33
260	Design and synthesis of new piperidone grafted acetylcholinesterase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 228-231.	1.0	23

#	ARTICLE	IF	Citations
261	Colorimetric assay of butyrylcholinesterase activity based on para-sulfonatocalix[4]arene-modified gold nanoparticles. Sensors and Actuators B: Chemical, 2017, 251, 869-876.	4.0	11
262	Ferrocenylaniline based amide analogs of methoxybenzoic acids: Synthesis, structural characterization and butyrylcholinesterase (BChE) inhibition studies. Journal of Molecular Structure, 2017, 1146, 130-137.	1.8	7
263	Semisynthesis and biological evaluation of prenylated resveratrol derivatives as multi-targeted agents for Alzheimer's disease. Journal of Natural Medicines, 2017, 71, 665-682.	1.1	28
264	Synthesis, biochemical evaluation, and molecular modeling studies of aryl and arylalkyl di- n -butyl phosphates, effective butyrylcholinesterase inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 3171-3181.	1.4	11
265	Bioactivities of Achillea phrygia and Bupleurum croceum based on the composition of phenolic compounds: InÂvitro and in silico approaches. Food and Chemical Toxicology, 2017, 107, 597-608.	1.8	20
266	Synthesis and cholinesterase inhibitory activity study of new piperidone grafted spiropyrrolidines. Bioorganic Chemistry, 2017, 75, 210-216.	2.0	21
267	Synthesis and in vitro evaluation of novel N-cycloalkylcarbamates as potential cholinesterase inhibitors. Monatshefte FÃ $\frac{1}{4}$ r Chemie, 2017, 148, 2143-2153.	0.9	3
268	Acetamide Derivatives of Chromenâ€2â€ones as Potent Cholinesterase Inhibitors. Archiv Der Pharmazie, 2017, 350, 1700076.	2.1	4
269	New racemic annulated pyrazolo[1,2-b]phthalazines as tacrine-like AChE inhibitors with potential use in Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 139, 280-289.	2.6	45
270	1,2,4-Thiadiazole derivatives as effective NMDA receptor blockers with anticholinesterase activity and antioxidant properties. Russian Chemical Bulletin, 2017, 66, 1308-1313.	0.4	7
271	Comparative metabolism of DDAO benzoate in liver microsomes from various species. Toxicology in Vitro, 2017, 44, 280-286.	1.1	13
272	Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 360-371.	1.4	53
273	Etidronate rescues cognitive deficits through improving synaptic transmission and suppressing apoptosis in 2â€vessel occlusion model rats. Journal of Neurochemistry, 2017, 140, 476-484.	2.1	21
274	Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 125, 853-864.	2.6	95
275	Synthesis of new N-(pyridin-3-ylmethyl)-2-aminothiazoline derivatives possessing anticholinesterase and antiradical activity as potential multifunctional agents for the treatment of neurodegenerative diseases. Russian Chemical Bulletin, 2017, 66, 1897-1904.	0.4	0
276	Rapid Mechanistic Evaluation and Parameter Estimation of Putative Inhibitors in a Single-Step Progress-Curve Analysis: The Case of Horse Butyrylcholinesterase. Molecules, 2017, 22, 1248.	1.7	8
277	COGNITIVE-ENHANCING PROPERTIES OF MORINDA LUCIDA (RUBIACEAE) AND PELTOPHORUM PTEROCARPUM (FABACEAE) IN SCOPOLAMINE-INDUCED AMNESIC MICE. Tropical Journal of Obstetrics and Gynaecology, 2017, 14, 136-141.	0.3	5
278	Cholinesterase and Prolyl Oligopeptidase Inhibitory Activities of Alkaloids from Argemone platyceras (Papaveraceae). Molecules, 2017, 22, 1181.	1.7	19

#	Article	IF	CITATIONS
279	Hippeastrum reticulatum (Amaryllidaceae): Alkaloid Profiling, Biological Activities and Molecular Docking. Molecules, 2017, 22, 2191.	1.7	23
280	Ensemble Molecular Dynamics of a Protein-Ligand Complex: Residual Inhibitor Entropy Enhances Drug Potency in Butyrylcholinesterase. Bioenergetics: Open Access, 2017, 06, .	0.1	4
281	2-Aryl-3-(arylideneamino)-1,2-dihydroquinazoline-4($3 < i > H < / i >$)-ones as inhibitors of cholinesterases and self-induced \hat{I}^2 -amyloid (\hat{AI}^2) aggregation: biological evaluations and mechanistic insights from molecular dynamics simulations. RSC Advances, 2018, 8, 7818-7831.	1.7	6
282	Cholinesterase inhibitory alkaloids from the rhizomes of Coptis chinensis. Bioorganic Chemistry, 2018, 77, 625-632.	2.0	12
283	Development and characterization of morin hydrate-loaded micellar nanocarriers for the effective management of Alzheimer's disease. Journal of Microencapsulation, 2018, 35, 137-148.	1.2	24
284	Ebselen inhibits the activity of acetylcholinesterase globular isoform G4 in vitro and attenuates scopolamineâ€induced amnesia in mice. Journal of Cellular Biochemistry, 2018, 119, 5598-5608.	1.2	23
285	Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease. MedChemComm, 2018, 9, 357-370.	3.5	25
286	Novel donepezil-like N -benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine "bio-oxidizable―prodrugs: Synthesis, biological evaluation and structure-activity relationship. European Journal of Medicinal Chemistry, 2018, 145, 165-190.	2.6	29
287	Intramolecular cyclization of polyfluoroalkyl-containing 2-(arylhydrazinylidene)-1,3-diketones. Journal of Fluorine Chemistry, 2018, 210, 117-125.	0.9	7
288	The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity. Journal of Medicinal Chemistry, 2018, 61, 119-139.	2.9	112
289	Chromones: privileged scaffolds for the production of multi-target-directed-ligand agents for the treatment of Alzheimer's disease. Expert Opinion on Drug Discovery, 2018, 13, 1141-1151.	2.5	14
290	Designing Hybrids Targeting the Cholinergic System by Modulating the Muscarinic and Nicotinic Receptors: A Concept to Treat Alzheimer's Disease. Molecules, 2018, 23, 3230.	1.7	20
291	The Cholinergic System as a Treatment Target for Opioid Use Disorder. CNS Drugs, 2018, 32, 981-996.	2.7	22
292	Natural Therapeutics for Alzheimer's Disease. , 2018, , 227-245.		0
293	Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer's Disease: Present Status and Future Opportunities. Frontiers in Aging Neuroscience, 2018, 10, 284.	1.7	99
294	Probing the binding site of novel selective positive allosteric modulators at the M1 muscarinic acetylcholine receptor. Biochemical Pharmacology, 2018, 154, 243-254.	2.0	19
295	A patent review of butyrylcholinesterase inhibitors and reactivators 2010–2017. Expert Opinion on Therapeutic Patents, 2018, 28, 455-465.	2.4	31
296	Beneficial Effects of Gagam-Palmultang on Scopolamine-Induced Memory Deficits in Mice. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-11.	0.5	4

#	Article	IF	Citations
297	Synthesis and biological evaluation of new tetramethylpyrazineâ€based chalcone derivatives as potential antiâ€Alzheimer agents. Chemical Biology and Drug Design, 2018, 92, 1859-1866.	1.5	40
298	Red blood cell acetylcholinesterase activity among healthy dwellers of an agrarian region in Sri Lanka: a descriptive cross-sectional study. Environmental Health and Preventive Medicine, 2018, 23, 25.	1.4	5
299	Stereoselective glucuronidation metabolism, pharmacokinetics, anti-amnesic pharmacodynamics, and toxic properties of vasicine enantiomers in vitro and in vivo. European Journal of Pharmaceutical Sciences, 2018, 123, 459-474.	1.9	10
300	Ethnopharmacological Approaches for Dementia Therapy and Significance of Natural Products and Herbal Drugs. Frontiers in Aging Neuroscience, 2018, 10, 3.	1.7	93
301	Cholinesterase Inhibition Activity, Alkaloid Profiling and Molecular Docking of Chilean Rhodophiala (Amaryllidaceae). Molecules, 2018, 23, 1532.	1.7	34
302	Unexpected protonation state of Glu197 discovered from simulations of tacrine in butyrylcholinesterase. Physical Chemistry Chemical Physics, 2018, 20, 14938-14946.	1.3	7
303	Organoruthenium Prodrugs as a New Class of Cholinesterase and Glutathioneâ€Sâ€Transferase Inhibitors. ChemMedChem, 2018, 13, 2166-2176.	1.6	23
304	Acetyl- and butyrylcholinesterase inhibitory activity of selected photochemicallysynthesized polycycles. Turkish Journal of Chemistry, 2019, 43, 1170-1182.	0.5	11
305	Novel 12-hydroxydehydroabietylamine derivatives act as potent and selective butyrylcholinesterase inhibitors. Bioorganic Chemistry, 2019, 90, 103092.	2.0	12
306	Fucoidan-Rich Substances from Ecklonia cava Improve Trimethyltin-Induced Cognitive Dysfunction via Down-Regulation of Amyloid \hat{l}^2 Production/Tau Hyperphosphorylation. Marine Drugs, 2019, 17, 591.	2.2	33
307	Don't forget astrocytes when targeting Alzheimer's disease. British Journal of Pharmacology, 2019, 176, 3585-3598.	2.7	40
308	Botryane terpenoids produced by Nemania bipapillata, an endophytic fungus isolated from red alga Asparagopsis taxiformis - Falkenbergia stage. Scientific Reports, 2019, 9, 12318.	1.6	33
309	Selective BuChE inhibitory activity, chemical composition, and enantiomer content of the volatile oil from the Ecuadorian plant Clinopodium brownei. Revista Brasileira De Farmacognosia, 2019, 29, 749-754.	0.6	16
310	Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder. Journal of Substance Abuse Treatment, 2019, 107, 29-37.	1.5	14
311	Synthesis and Molecular Modeling Studies on Novel C2 Alkylated Benzoazonine Scaffold and Corresponding 2-Pyrazoline Derivatives as Acetylcholinestrase Enzyme Inhibitors. Polycyclic Aromatic Compounds, 2021, 41, 1223-1240.	1.4	3
312	Critical evaluation of current Alzheimer's drug discovery (2018–19) & futuristic Alzheimer drug model approach. Bioorganic Chemistry, 2019, 93, 103299.	2.0	20
313	Isoquinoline Alkaloids from <i>Berberis vulgaris</i> as Potential Lead Compounds for the Treatment of Alzheimer's Disease. Journal of Natural Products, 2019, 82, 239-248.	1.5	55
314	Rosmarinic acid suppresses Alzheimer's disease development by reducing amyloid β aggregation by increasing monoamine secretion. Scientific Reports, 2019, 9, 8711.	1.6	82

#	Article	IF	CITATIONS
315	LC-ESI-MS/MS Phenolic Profile of Volutaria lippii (L.) Cass. Extracts and Evaluation of Their In Vitro Antioxidant, Antiacetylcholinesterase, Antidiabetic, and Antibacterial Activities. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-13.	0.5	10
316	The mechanism and benefit of human butyrylcholinesterase activation by what would otherwise be inhibitors. Chemico-Biological Interactions, 2019, 308, 350-356.	1.7	5
317	Comparative biophysical characterization: A screening tool for acetylcholinesterase inhibitors. PLoS ONE, 2019, 14, e0215291.	1.1	12
318	Aminoalkyl-substituted flavonoids: synthesis, cholinesterase inhibition, \hat{l}^2 -amyloid aggregation, and neuroprotective study. Medicinal Chemistry Research, 2019, 28, 974-983.	1.1	9
319	Synthesis and biological evaluation of 3–(4-aminophenyl)-coumarin derivatives as potential anti-Alzheimer's disease agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 1083-1092.	2.5	23
320	Feasibility and effects of galantamine on cognition in humans with cannabis use disorder. Pharmacology Biochemistry and Behavior, 2019, 181, 86-92.	1.3	10
321	Highly selective carbamate-based butyrylcholinesterase inhibitors derived from a naturally occurring pyranoisoflavone. Bioorganic Chemistry, 2019, 88, 102949.	2.0	17
322	New benzyl pyridinium derivatives bearing 2,4-dioxochroman moiety as potent agents for treatment of Alzheimer's disease: Design, synthesis, biological evaluation, and docking study. Bioorganic Chemistry, 2019, 87, 506-515.	2.0	15
323	Drug-1,3,4-Thiadiazole Conjugates as Novel Mixed-Type Inhibitors of Acetylcholinesterase: Synthesis, Molecular Docking, Pharmacokinetics, and ADMET Evaluation. Molecules, 2019, 24, 860.	1.7	22
324	In Vitro and In Silico Acetylcholinesterase Inhibitory Activity of Thalictricavine and Canadine and Their Predicted Penetration across the Blood-Brain Barrier. Molecules, 2019, 24, 1340.	1.7	23
325	Natural cholinesterase inhibitors from marine organisms. Natural Product Reports, 2019, 36, 1053-1092.	5.2	66
326	Innovative Therapy for Alzheimer's Disease-With Focus on Biodelivery of NGF. Frontiers in Neuroscience, 2019, 13, 38.	1.4	103
327	A fluorescent probe for butyrylcholinesterase activity in human serum based on a fluorophore with specific binding affinity for human serum albumin. Chemical Communications, 2019, 55, 14574-14577.	2.2	41
328	Anticholinesterase and Antioxidant Potential of Hydromethanolic Extract of (i>Ziziphus mucronata()i>(Rhamnaceae) Leaves on Scopolamine-Induced Memory and Cognitive Dysfunctions in Mice. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-14.	0.5	19
329	Natural Multiâ€Target Inhibitors of Cholinesterases and Monoamine Oxidase Enzymes with Antioxidant Potential from Skin Extracts of <i>Hypsiboas cordobae</i> and <i>Pseudis minuta</i> (Anura: Hylidae). Chemistry and Biodiversity, 2019, 16, e1800472.	1.0	12
330	No interaction between rivastigmine and citalopram on memory and novelty processing in healthy human volunteers. Journal of Psychopharmacology, 2019, 33, 210-218.	2.0	2
331	Classics in Chemical Neuroscience: Donepezil. ACS Chemical Neuroscience, 2019, 10, 155-167.	1.7	37
332	An immobilized acetylcholinesterase as test system to screen new inhibitor drugs to treat Alzheimer's disease. Sensors and Actuators B: Chemical, 2019, 278, 196-201.	4.0	9

#	Article	IF	CITATIONS
333	Gene Expressions, Hippocampal Volume Loss and MMSE Scores in Computation of Progression and Pharmacologic Therapy Effects for Alzheimer's Disease. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2019, 17, 1-1.	1.9	2
334	Understanding the enzyme–ligand complex: insights from all-atom simulations of butyrylcholinesterase inhibition. Journal of Biomolecular Structure and Dynamics, 2020, 38, 1028-1041.	2.0	8
335	Modeling and synthesis of novel oxime derivatives as potential cholinesterase inhibitors. Journal of Molecular Structure, 2020, 1200, 127149.	1.8	10
336	Online acetylcholinesterase inhibition evaluation by high-performance liquid chromatography–mass spectrometry hyphenated with an immobilized enzyme reactor. Journal of Chromatography A, 2020, 1609, 460506.	1.8	11
337	5,6-Diphenyl triazine-thio methyl triazole hybrid as a new Alzheimer's disease modifying agents. Molecular Diversity, 2020, 24, 641-654.	2.1	25
338	Novel AChE and BChE inhibitors using combined virtual screening, text mining and in vitro binding assays. Journal of Biomolecular Structure and Dynamics, 2020, 38, 3342-3358.	2.0	11
339	Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. RSC Medicinal Chemistry, 2020, 11, 225-233.	1.7	26
340	Synthesis and biological evaluation of 4-arylcoumarins as potential anti-Alzheimer's disease agents. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126900.	1.0	13
341	A review on gentisic acid as a plant derived phenolic acid and metabolite of aspirin: Comprehensive pharmacology, toxicology, and some pharmaceutical aspects. Phytotherapy Research, 2020, 34, 729-741.	2.8	85
342	Water-soluble betaines and amines based on thiacalix[4] arene scaffold as new cholinesterase inhibitors. Bioorganic Chemistry, 2020, 94, 103455.	2.0	10
343	Design, synthesis and cholinesterase inhibitory properties of new oxazole benzylamine derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 460-467.	2.5	11
344	Molecular recognition of acetylcholinesterase and its subnanomolar reversible inhibitor: a molecular simulations study. Journal of Biomolecular Structure and Dynamics, 2022, 40, 1671-1691.	2.0	2
345	Synthesis, characterization, acetylcholinesterase inhibition, and molecular docking studies of new piperazine substituted dihydrofuran compounds. Medicinal Chemistry Research, 2020, 29, 1804-1818.	1.1	14
346	The impact of some phenolic compounds on serum acetylcholinesterase: kinetic analysis of an enzyme/inhibitor interaction and molecular docking study. Journal of Biomolecular Structure and Dynamics, 2021, 39, 6515-6523.	2.0	18
347	New Insights into the Exploitation of Vitis vinifera L. cv. Aglianico Leaf Extracts for Nutraceutical Purposes. Antioxidants, 2020, 9, 708.	2.2	15
348	Traditional Chinese medicine for anti-Alzheimer's disease: berberine and evodiamine from Evodia rutaecarpa. Chinese Medicine, 2020, 15, 82.	1.6	39
349	Benzobicyclo[3.2.1]octene Derivatives as a New Class of Cholinesterase Inhibitors. Molecules, 2020, 25, 4872.	1.7	4
350	Nitrogenâ€containing flavonoid and their analogs with diverse Bâ€ring in acetylcholinesterase and butyrylcholinesterase inhibition. Drug Development Research, 2020, 81, 1037-1047.	1.4	5

#	Article	IF	CITATIONS
351	Osmotic Dehydration as a Pretreatment Modulating the Physicochemical and Biological Properties of the Japanese Quince Fruit Dried by the Convective and Vacuum-Microwave Method. Food and Bioprocess Technology, 2020, 13, 1801-1816.	2.6	19
352	A comparative study on chemical profile and biological activities of aerial parts (stems, flowers,) Tj ETQq1 1 0.784	314 rgBT / 1.5	Overlock 10
	27, 101668.		
353	The two faces of Coprinus comatus â€"Functional properties and potential hazards. Phytotherapy Research, 2020, 34, 2932-2944.	2.8	20
354	Design and synthesis of 2,4â€dioxochromanâ€pyridiniumâ€phenylacetamide derivatives as new antiâ€Alzheimer agents: in vitro and in silico studies. Journal of the Chinese Chemical Society, 2020, 67, 1910-1928.	0.8	O
355	Novel Acetylcholinesterase Inhibitors Identified from ZINC Database Using Dockingâ€Based Virtual Screening for Alzheimer's Disease ChemistrySelect, 2020, 5, 3593-3599.	0.7	6
356	Pharmacotechnical Development of a Nasal Drug Delivery Composite Nanosystem Intended for Alzheimer's Disease Treatment. Pharmaceutics, 2020, 12, 251.	2.0	43
357	8-Hydroxyquinoline-based anti-Alzheimer multimodal agents. Monatshefte FÃ $\frac{1}{4}$ r Chemie, 2020, 151, 1111-1120.	0.9	10
358	Exploring the Multi-Target Performance of Mitochondriotropic Antioxidants against the Pivotal Alzheimer's Disease Pathophysiological Hallmarks. Molecules, 2020, 25, 276.	1.7	9
359	Design, Synthesis, and Evaluation of Acetylcholinesterase and Butyrylcholinesterase Dual-Target Inhibitors against Alzheimer's Diseases. Molecules, 2020, 25, 489.	1.7	12
360	Alkaloid profile and cholinesterase inhibition activity of five species of Amaryllidaceae family collected from Mérida state-Venezuela. South African Journal of Botany, 2021, 136, 126-136.	1.2	18
361	<i>Citrus spp</i> . essential oils improve behavioral pattern, repressed cholinesterases and monoamine oxidase activities, and production of reactive species in fruit fly (<i>Drosophila) Tj ETQq0 0 0 rgBT /Ov</i>	v er zkock 10	7f 50 337 ī
362	Treating disorders across the lifespan by modulating cholinergic signaling with galantamine. Journal of Neurochemistry, 2021, 158, 1359-1380.	2.1	26
363	Interactions of dye compounds that are structurally related to methylene blue with acetylcholinesterase and butyrylcholinesterase. Chemical Biology and Drug Design, 2021, 97, 854-864.	1.5	3
364	Microwave-assisted synthesis, biological assessment, and molecular modeling of aza-heterocycles: Potential inhibitory capacity of cholinergic enzymes to Alzheimer's disease. Journal of Molecular Structure, 2021, 1224, 129307.	1.8	7
365	Tacrine and its 7-methoxy derivate; time-change concentration in plasma and brain tissue and basic toxicological profile in rats. Drug and Chemical Toxicology, 2021, 44, 207-214.	1.2	6
366	Progressive Insights into the Pharmacological Importance of Isoquinoline Derivatives in Modern Therapeutics. International Journal of Current Research and Review (discontinued), 2021, 13, 83-90.	0.1	1
367	Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies. Bioorganic and Medicinal Chemistry Letters, 2021, 34, 127756.	1.0	7
368	Biological evaluation and molecular docking of novel 1,3,4-thiadiazole-resorcinol conjugates as multifunctional cholinesterases inhibitors. Bioorganic Chemistry, 2021, 107, 104617.	2.0	19

#	Article	IF	CITATIONS
369	Design and Friedlander Reaction Based Synthesis of New Cycloalkyl Ring Fused Quinolines as Multifunctional Agents for Alzheimer's Treatment: In Silico Studies. ChemistrySelect, 2021, 6, 1947-1957.	0.7	2
370	Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease. European Journal of Pharmacology, 2021, 895, 173875.	1.7	9
371	Trimethoxycinnamates and Their Cholinesterase Inhibitory Activity. Applied Sciences (Switzerland), 2021, 11, 4691.	1.3	5
373	In vitro antioxidant activity and enzyme inhibition properties of wheat whole grain, bran and flour defatted with hexane and supercritical fluid extraction. LWT - Food Science and Technology, 2021, 146, 111376.	2.5	13
374	Essential Oil Content, Antioxidative Characteristics and Enzyme Inhibitory Activity of <i>Sideritis akmanii</i> Aytaç, Ekici & Dönmez. Turkish Journal of Pharmaceutical Sciences, 2022, 19, 76-83.	0.6	4
375	Huprine Y – Tryptophan heterodimers with potential implication to Alzheimer's disease treatment. Bioorganic and Medicinal Chemistry Letters, 2021, 43, 128100.	1.0	5
376	4-Phenethyl-1-Propargylpiperidine-Derived Dual Inhibitors of Butyrylcholinesterase and Monoamine Oxidase B. Molecules, 2021, 26, 4118.	1.7	5
377	Novel Sulfonamide-Based Carbamates as Selective Inhibitors of BChE. International Journal of Molecular Sciences, 2021, 22, 9447.	1.8	11
378	In-vitro evaluation of antioxidant and anticholinesterase activities of novel pyridine, quinoxaline and s-triazine derivatives. Environmental Research, 2021, 199, 111320.	3.7	28
379	Acetylcholinesterase inhibition, molecular docking and ADME prediction studies of new dihydrofuran-piperazine hybrid compounds. Medicinal Chemistry Research, 2021, 30, 2114.	1.1	4
380	Investigating Neuroprotective Potential of Berberine, Levetiracetam and their Combination in the Management of Alzheimer's Disease Utilizing Drug Repurposing Strategy. Current Reviews in Clinical and Experimental Pharmacology, 2023, 18, 182-190.	0.4	5
381	Pharmacotherapeutic Potential of Garlic in Age-Related Neurological Disorders. CNS and Neurological Disorders - Drug Targets, 2021, 20, .	0.8	5
382	Discovery of 1-(phenylsulfonyl)-1H-indole-based multifunctional ligands targeting cholinesterases and 5-HT6 receptor with anti-aggregation properties against amyloid-beta and tau. European Journal of Medicinal Chemistry, 2021, 225, 113783.	2.6	11
383	Synthesis, structural properties and potent bioactivities supported by molecular docking and DFT studies of new hydrazones derived from 5-chloroisatin and 2-thiophenecarboxaldehyde. Journal of Molecular Structure, 2021, 1246, 131204.	1.8	12
384	Development and crystallography-aided SAR studies of multifunctional BuChE inhibitors and 5-HT6R antagonists with \hat{I}^2 -amyloid anti-aggregation properties. European Journal of Medicinal Chemistry, 2021, 225, 113792.	2.6	13
385	Alzheimer's Disease, Schizophrenia and Depression. , 2011, , 377-415.		1
386	In vitro screening of the acetylcholinesterase inhibition, antioxidant activity, and neuronal cell protective effect of medicinal plant extracts. Korean Journal of Food Preservation, 2013, 20, 840-845.	0.2	8
388	Troxerutin protects hippocampal neurons against amyloid beta-induced oxidative stress and apoptosis. EXCLI Journal, 2017, 16, 1081-1089.	0.5	37

#	ARTICLE	IF	CITATIONS
389	Evaluation of phenolic profile, antioxidant and anticholinesterase effects of Fuscoporia torulosa. International Journal of Secondary Metabolite, 2019, 6, 79-89.	0.5	2
390	Memantine combined with an acetyl cholinesterase inhibitor? hope for the future?. Neuropsychiatric Disease and Treatment, 2006, 2, 121-125.	1.0	7
391	The Effects of Soluble A.β Oligomers on Neurodegeneration in Alzheimer's Disease. Current Pharmaceutical Design, 2014, 20, 2506-2519.	0.9	30
392	A Recent Look into Natural Products that have Potential to Inhibit Cholinesterases and Monoamine Oxidase B: Update for 2010-2019. Combinatorial Chemistry and High Throughput Screening, 2020, 23, 862-876.	0.6	6
393	Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool. Current Protein and Peptide Science, 2020, 21, 99-109.	0.7	42
394	Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry, 2020, 20, 703-715.	1.1	68
395	N-alkylated Tacrine Derivatives as Potential Agents in Alzheimer's Disease Therapy. Current Alzheimer Research, 2019, 16, 333-343.	0.7	5
396	From Protein Communication to Drug Discovery. Current Topics in Medicinal Chemistry, 2015, 15, 2019-2031.	1.0	7
397	Acetylcholinesterase Inhibitors: Pharmacology and Toxicology. Current Neuropharmacology, 2013, 11, 315-335.	1.4	1,718
398	Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors-Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment. Current Neuropharmacology, 2017, 15, 637-653.	1.4	21
399	Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design. Current Neuropharmacology, 2018, 16, 649-663.	1.4	30
400	Efficient Synthesis and Discovery of Schiff Bases as Potent Cholinesterase Inhibitors. Medicinal Chemistry, 2016, 12, 527-536.	0.7	7
401	Perspective Design of Chalcones for the Management of CNS Disorders: A Mini-Review. CNS and Neurological Disorders - Drug Targets, 2019, 18, 432-445.	0.8	34
402	Donepezil and Rivastigmine: Pharmacokinetic Profile and Brain-targeting After Intramuscular Administration in Rats. Iranian Journal of Pharmaceutical Research, 2020, 19, 95-102.	0.3	4
404	Effects of simvastatin and fenofibrate on butyrylcholinesterase activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats. Arhiv Za Higijenu Rada I Toksikologiju, 2019, 70, 30-35.	0.4	3
405	Antidepressant in animal models of depression and study of cognitive property. GSC Biological and Pharmaceutical Sciences, 2019, 7, 064-076.	0.1	1
406	Effects of the Deer Antler Extract on Scopolamine-induced Memory Impairment and Its Related Enzyme Activities. Journal of the Korean Society of Food Science and Nutrition, 2009, 38, 409-414.	0.2	6
407	Assessment of Neuropharmacological Activities of <i>Terminalia Chebula</i> in Rats. American Journal of Pharmacology and Toxicology, 2012, 7, 41-48.	0.7	3

#	Article	IF	CITATIONS
408	L-3-n-butylphthalide protects against vascular dementia via activation of the Akt kinase pathway. Neural Regeneration Research, 2013, 8, 1733-42.	1.6	22
409	Dual inhibition of acetylcholinesterase and butyrylcholinesterase enzymes by allicin. Indian Journal of Pharmacology, 2015, 47, 444.	0.4	44
410	Studies On Thiazolyl-Hydrazone Derivatives As Acetylcholinesterase Inhibitors. Journal of Marmara University Institute of Health Sciences, 2014, , 1.	0.1	5
411	CHOLINESTERASES, A TARGET OF PHARMACOLOGY AND TOXICOLOGY. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2011, 155, 219-223.	0.2	281
412	Antioxidant, Anti-acetylcholinesterase and Composition of Biochemical Components of Russian Deer Velvet Antler Extracts. Korean Journal for Food Science of Animal Resources, 2011, 31, 349-355.	1.5	5
413	Analysis of Salvia miltiorrhiza (Danshen). African Journal of Microbiology Research, 2012, 6, .	0.4	1
414	Association of CYP2D6 (G1934A) gene and hematological disturbances in chronic pesticide exposures. Journal of Applied Pharmaceutical Science, 0, , .	0.7	1
415	Potent and Selective Inhibitors of Human Monoamine Oxidase A from an Endogenous Lichen Fungus Diaporthe mahothocarpus. Journal of Fungi (Basel, Switzerland), 2021, 7, 876.	1.5	6
416	Multitarget 2′-hydroxychalcones as potential drugs for the treatment of neurodegenerative disorders and their comorbidities. Neuropharmacology, 2021, 201, 108837.	2.0	6
417	EL SÃNDROME DE DOWN EN EL SIGLO XXI. EnfermerÃa Actual De Costa Rica, 2012, , .	0.2	0
418	Butyrylcholinesterase and Its Synthetic C-Terminal Peptide Confer In Vitro Suppression of Amyloid Fibril Formation., 2007,,.		0
419	Alzheimer's Disease—is it Caused by Cerebrovascular Dysfunction?. , 2009, , 369-384.		0
421	Metal ion roles and responses in the CNS under toxic organophosphonate exposure: traces of understanding and various open questions., 2012,, 173-176.		0
422	Therapeutic Opportunities in Alzheimer Disease: Current Concepts., 2012,, 767-788.		0
423	In vitro inhibitory effect of Boeserngin A on human acetylcholinerase: understanding its potential using in silico ADMET studies. Journal of Applied Pharmaceutical Science, 0, , .	0.7	0
424	In Vitro Inhibition of Human Plasma and Erythrocyte AChE by Various Drugs. Hacettepe Journal of Biology and Chemistry, 2016, 3, 217-217.	0.3	0
425	Role of Artemisia macrocephala as enzymes inhibitor in dementia and nociception! A pharmacological study. Pure and Applied Biology, 2016, 5, .	0.1	0
426	N-Phenacylthiazolium Salts as Inhibitors of Cholinesterases. French-Ukrainian Journal of Chemistry, 2017, 5, 1-14.	0.1	2

#	Article	IF	CITATIONS
427	Evaluation of the bioassay of Commiphora molmol extract (Mirazid) against praziquantel in experimentally infected mice with Schistosoma mansoni. Journal of Veterinary Medical Research, 2017, 24, 94-102.	0.2	1
428	Synthesis, in vitro Acetylcholinesterase Inhibitory Activity Evaluation and Docking Investigation of Some Aromatic Chalcones. Y Hoc Thanh Pho Ho Chi Minh, 2017, 1, 15-25.	0.1	o
430	In silico chemical profiling and identification of neuromodulators from Curcuma amada targeting acetylcholinesterase. Network Modeling Analysis in Health Informatics and Bioinformatics, 2021, 10, 1.	1.2	1
431	Functional Analysis and Molecular Docking studies of Medicinal Compounds for AChE and BChE in Alzheimer's Disease and Type 2 Diabetes Mellitus. , 2013, 4, 186-200.		1
432	In vitro anticholinergic and antihistaminic activities of Acorus calamus Linn. leaves extracts. African Journal of Traditional Complementary and Alternative Medicines, 2012, 10, 95-101.	0.2	4
434	Coumarin derivatives bearing benzoheterocycle moiety: synthesis, cholinesterase inhibitory, and docking simulation study. Iranian Journal of Basic Medical Sciences, 2017, 20, 631-638.	1.0	7
435	Iminoâ€2 <i>H</i> àê€Chromene Based Derivatives as Potential Antiâ€Alzheimer's Agents: Design, Synthesis, Biological Evaluation and <i>in Silico</i> Study. Chemistry and Biodiversity, 2022, 19, e2100599.	1.0	4
436	Essential Oils from Spices Inhibit Cholinesterase Activity and Improve Behavioral Disorder in AlCl3 Induced Dementia. Chemistry and Biodiversity, 2021, , e2100443.	1.0	10
437	Screening and identification of acetylcholinesterase inhibitors from Terminalia chebula fruits by immobilized enzyme on cellulose filter paper coupled with ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry and molecular docking. Journal of Chromatography A, 2022, 1663, 462784.	1.8	5
438	Cholinesterases and Their Inhibitors. Biochemistry, 0, , .	0.8	O
439	Alkaloid Profiling and Cholinesterase Inhibitory Potential of Crinum × amabile Donn. (Amaryllidaceae) Collected in Ecuador. Plants, 2021, 10, 2686.	1.6	5
441	Natural Products from Plants and Algae for Treatment of Alzheimer's Disease: A Review. Biomolecules, 2022, 12, 694.	1.8	12
442	In Vitro and In Silico Evaluation of Cholinesterase Inhibition by Alkaloids Obtained from Branches of Abuta panurensis Eichler. Molecules, 2022, 27, 3138.	1.7	3
443	Evaluation of anti-amnesic effect of in rats Indian Journal of Pharmacology, 2022, 54, 102-109.	0.4	O
444	Medha Plus – A novel polyherbal formulation ameliorates cognitive behaviors and disease pathology in models of Alzheimer's disease. Biomedicine and Pharmacotherapy, 2022, 151, 113086.	2.5	5
445	Drug Distribution in Brain and Cerebrospinal Fluids in Relation to IC50 Values in Aging and Alzheimer's Disease, Using the Physiologically Based LeiCNS-PK3.0 Model. Pharmaceutical Research, 2022, 39, 1303-1319.	1.7	3
446	Synthesis and QSAR of Novel Ketoprofen–Chalcone-Amide Hybrides as Acetylcholinesterase (AChE) Inhibitors for Possible Treatment of Alzheimer Disease. Russian Journal of Bioorganic Chemistry, 0, , .	0.3	0
447	Alkaloid Composition and Biological Activities of the Amaryllidaceae Species Ismene amancaes (Ker) Tj ETQq $1\ 1$	0.7 <u>84</u> 314	rgBT /Overloc

#	Article	IF	CITATIONS
448	Design synthesis and In vitro evaluation of Tacrine- Flavone hybrids as Multifunctional Cholinesterase inhibitors for Alzheimer's disease. Current Computer-Aided Drug Design, 2022, 18, .	0.8	1
449	Design, synthesis, acetylcholinesterase, butyrylcholinesterase, and amyloidâ $\hat{\mathfrak{e}}^2$ aggregation inhibition studies of substituted 4,4 $\hat{\mathfrak{e}}^1$ â $\hat{\mathfrak{e}}$ diimine/4,4 $\hat{\mathfrak{e}}^1$ â $\hat{\mathfrak{e}}$ diazobiphenyl derivatives. Archiv Der Pharmazie, 0, , .	2.1	0
450	Toluidine blue O attenuates tau phosphorylation in N2a-APPSwe cells. Chemico-Biological Interactions, 2022, 366, 110126.	1.7	2
451	Novel difluoromethylated 1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole derivatives as potent 5-HT6 receptor antagonist with AMDE-improving properties: Design, synthesis, and biological evaluation. Bioorganic and Medicinal Chemistry, 2022, 71, 116950.	1.4	0
452	Anti-Amnesic Effect of Curcumin Spray Dry Powders on Scopolamine-Induced Mouse Memory Impairment. Journal of the Korean Society of Food Science and Nutrition, 2022, 51, 751-764.	0.2	0
453	Ferocactus herrerae Fruits: Nutritional Significance, Phytochemical Profiling, and Biological Potentials. Plant Foods for Human Nutrition, 2022, 77, 545-551.	1.4	4
454	Design and synthesis of new indole drug candidates to treat Alzheimer's disease and targeting neuro-inflammation using a multi-target-directed ligand (MTDL) strategy. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 2660-2678.	2.5	8
455	Efficient one-pot synthesis of arylated pyrazole-fused pyran analogs: as leads to treating diabetes and Alzheimer's disease. Future Medicinal Chemistry, 2022, 14, 1507-1526.	1.1	3
456	Novel AP2238-clorgiline hybrids as multi-target agents for the treatment of Alzheimer's disease: Design, synthesis, and biological evaluation. Bioorganic Chemistry, 2023, 130, 106224.	2.0	7
457	The preventive effects of <i>Centaurea maroccana</i> Ball. extract against oxidative stress induced by cisplatin in mice brains: <i>inÂvitro</i> and <i>inÂvivo</i> studies. Drug and Chemical Toxicology, 2023, 46, 1162-1175.	1.2	3
458	New acetylcholinesterase inhibitors isolated from Delphinium uncinatum. Arabian Journal of Chemistry, 2023, 16, 104408.	2.3	0
459	Piperazine derivatives with potent drug moiety as efficient acetylcholinesterase, butyrylcholinesterase, and glutathione Sâ€transferase inhibitors. Journal of Biochemical and Molecular Toxicology, 2023, 37, .	1.4	3
460	Antiâ€Ovarian cancer potential, in silico studies and antiâ€alzheimer's disease effects of some natural compounds as cholinesterase inhibitors. Biotechnology and Applied Biochemistry, 0, , .	1.4	1
461	Cholinesterases Inhibition, Anticancer and Antioxidant Activity of Novel Benzoxazole and Naphthoxazole Analogs. Molecules, 2022, 27, 8511.	1.7	4
462	Biological Evaluation of Valeriana Extracts from Argentina with Potent Cholinesterase Inhibition for the Treatment of Neurodegenerative Disorders and Their Comorbiditiesâ€"The Case of Valeriana carnosa Sm. (Caprifoliaceae) Studied in Mice. Pharmaceuticals, 2023, 16, 129.	1.7	1
463	Sterubin protects against chemically-induced Alzheimer's disease by reducing biomarkers of inflammation- IL-6/ IL-β/ TNF-α and oxidative stress- SOD/MDA in rats. Saudi Journal of Biological Sciences, 2023, 30, 103560.	1.8	8
464	Lycopodiastrum casuarinoides: An overview of their phytochemicals, biological activities, structure-activity relationship, biosynthetic pathway and 13C NMR data. FA¬toterapA¬A¢, 2023, 165, 105425.	1.1	2
465	Benzophenone Derivatives with Histamine H3 Receptor Affinity and Cholinesterase Inhibitory Potency as Multitarget-Directed Ligands for Possible Therapy of Alzheimer's Disease. Molecules, 2023, 28, 238.	1.7	3

#	Article	IF	CITATIONS
466	Novel Organoruthenium(II) Complex C1 Selectively Inhibits Butyrylcholinesterase without Side Effects on Neuromuscular Transmission. International Journal of Molecular Sciences, 2023, 24, 2681.	1.8	0
467	Some Bioactivities of Isolated Apigenin-7-O-glucoside and Luteolin-7-O-glucoside. Applied Sciences (Switzerland), 2023, 13, 1503.	1.3	7
468	Biological Activities of the Alkaloids of the Calabar Bean. , 2023, , 169-224.		0
469	Discovery of novel dual acetylcholinesterase and butyrylcholinesterase inhibitors using machine learning and structure-based drug design. Journal of Molecular Structure, 2023, 1286, 135517.	1.8	4
470	Discovery of new, highly potent and selective inhibitors of BuChE - design, synthesis, in vitro and in vivo evaluation and crystallography studies. European Journal of Medicinal Chemistry, 2023, 249, 115135.	2.6	4
472	New Thienobenzo/Naphtho-Triazoles as Butyrylcholinesterase Inhibitors: Design, Synthesis and Computational Study. International Journal of Molecular Sciences, 2023, 24, 5879.	1.8	2
475	Environmental toxicants (OPs and heavy metals) in the diet: What are their repercussions on behavioral/neurological systems?., 2023,, 411-427.		0
480	Approved Cholinesterase Inhibitor-Based Derivatives: Synthesis and Their Biological Evaluation. , 2023, , 157-183.		O